登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603300 证券简称：海南华铁 公告编号：临2025-081 浙江海控南科华铁数智科技股份有限公司 关于2021年股票期权激励计划2025年第三季度自主行权结果暨股本变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次行权股票数量：浙江海控南科华铁数智科技股份有限公司（以下简称"公司"）2021年股票期权激 励计划（以下简称"本次激励计划"）于2025年第三季度行权且完成过户登记的股份共计6,133,360股。截 至2025年9月30日，2021年股票期权激励计划第四个行权期累计行权并完成股份过户登记6,133,360股股 票，占本次可行权股票期权总量的31.59%。 ● 本次行权股票上市流通时间：激励计划采用自主行权方式，行权所得股票于行权日后的第二个交易日 上市交易。 一、本次股票期权行权的决策程序及相关信息披露 2021年6月3日，公司召开第四届董事会第八次会议，审议通过了《浙江华铁应急设备科技股份有限公司 2021年股票期权激励 ...

证券代码：600250 证券简称：南京商旅 公告编号：2025-060 本次注销股票期权事项符合《上市公司股权激励管理办法》、公司激励计划等相关规定，不会影响公司 股本结构，不会对公司的财务状况和经营成果产生重大影响。 特此公告 南京商贸旅游股份有限公司 董事会 2025年10月11日 南京商贸旅游股份有限公司 关于2021年股票期权激励计划部分股票期权注销完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 南京商贸旅游股份有限公司（以下简称南京商旅或公司）于2025年9月26日召开第十一届十四次董事会 和第十一届十一次监事会，审议通过了《关于注销2021年股票期权激励计划部分股票期权的议案》，同 意对公司2021年股票期权激励计划（以下简称激励计划）第二个行权期内一名激励对象因个人原因辞职 而不再符合行权条件的52,800份股票期权进行注销。具体内容详见公司于2025年9月27日披露的《关于 注销2021年股票期权激励计划部分股票期权的公告》。 经中国证券登记结算有限责任公司上海分公司审核确认，上述52,800份股票 ...

Core Points - The company announced the results of the third exercise period of its 2021 second stock option incentive plan, with a total of 3,134,800 shares available for exercise [1] - As of the end of Q3 2025, a total of 1,927,800 shares have been exercised, representing 61.50% of the total available [1] - The exercise price for the stock options has been adjusted multiple times, currently set at 21.30 yuan per share [4][3] Group 1: Stock Option Incentive Plan - The 2021 second stock option incentive plan was approved in November 2021, granting a total of 9,720,000 stock options to 10 incentive objects at an initial exercise price of 22.00 yuan per share [2] - The first grant of stock options occurred on December 3, 2021, with 9,220,000 options awarded [3] - The exercise period for the third phase is from December 17, 2024, to December 2, 2025, with shares listed for trading on T+2 after exercise [1][7] Group 2: Exercise and Registration Details - In Q3 2025, a total of 384,386 shares were exercised and registered, with the funds raised amounting to 8,187,421.80 yuan, which will be used to supplement the company's working capital [12] - The number of participants in the exercise was 8 out of 10 eligible individuals [6] - The shares obtained through the exercise are unrestricted and can be traded freely [8] Group 3: Convertible Bonds - The company issued convertible bonds named "Zhengfan Convertible Bonds" starting from March 18, 2025, with a total issuance amount of 1,041,095,000 yuan [18] - From September 24 to September 30, 2025, a total of 480 shares were converted from the bonds, representing 0.0002% of the total shares before conversion [15][20] - As of September 30, 2025, 1,041,076,000 yuan of the convertible bonds remained unconverted, accounting for 99.9982% of the total issuance [16][20]

Core Viewpoint - The announcement details the conversion of convertible bonds and the results of the 2023 stock option incentive plan, highlighting low conversion rates and the status of unconverted bonds [2][6][18]. Convertible Bond Conversion Status - From September 1 to September 30, 2025, a total of 42,000 yuan of "Changqi Convertible Bonds" were converted into 1,072 shares of company stock [2][6]. - Cumulatively, from December 17, 2021, to September 30, 2025, 4,942,000 yuan of "Changqi Convertible Bonds" have been converted into 129,601 shares, representing 0.0014% of the company's total shares before conversion [2][6]. - As of September 30, 2025, the amount of unconverted convertible bonds stands at 3,495,057,000 yuan, accounting for 99.8588% of the total issuance [2][6]. 2023 Stock Option Incentive Plan - The first exercise period of the 2023 stock option incentive plan allows for the exercise of 18,948,783 stock options, with the exercise period running from May 12, 2025, to January 25, 2026 [2][7]. - As of September 30, 2025, only 31 shares have been exercised under the plan, with a total of 834.07 yuan raised for working capital [17]. - The exercise price for the stock options is set at 26.47 yuan per share [17]. Company Actions and Share Capital Changes - The company has conducted several stock buybacks and cancellations due to various reasons, including the departure of incentive plan participants, resulting in the cancellation of 1,075,400 shares [18]. - The company has fulfilled the necessary procedures to notify creditors and has submitted applications for the cancellation of shares to the relevant authorities [18].

Core Viewpoint - The announcement details the stock option incentive plan of Zhejiang Kangnbei Pharmaceutical Co., Ltd. for the third quarter of 2025, highlighting the number of shares exercised and the related procedures [1][2]. Summary by Sections Stock Option Exercise Details - In the third quarter of 2025, a total of 3.604973 million shares were exercised under the 2022 stock option incentive plan [2]. - The exercised shares will be tradable on the second trading day after the exercise date [2]. Decision-Making Process and Information Disclosure - The plan was approved by the board and supervisory committee in September 2022, with detailed disclosures made on the Shanghai Stock Exchange and other designated media [2][3]. - The plan included the granting of 70 million stock options to eligible participants, with the first grant completed in November 2022 [3]. Adjustments to Stock Option Terms - The exercise price of the stock options was adjusted from 4.13 CNY to 3.98 CNY in June 2023, and further adjustments were made in July 2024 and June 2025 [3][4][5]. - The number of stock options granted was also adjusted, with 752.5 thousand reserved options granted in October 2023 [3][4]. Shareholder and Management Participation - A total of 97 participants exercised their options in the third quarter of 2025 [7]. - The shares resulting from the exercise are subject to a six-month lock-up period for directors and senior management [10]. Financial Impact and Fund Utilization - The exercise of options raised approximately 13.086052 million CNY, contributing to a total of 69.266768 million CNY raised to date, which will be used to supplement the company's working capital [12]. - The impact of the exercised shares on the company's financial status and operational results is not considered significant [12].

Core Points - The announcement details the stock option exercise results for the third quarter of 2025, indicating a total of 2,501,955 shares were exercised [1][26] - The exercise of stock options is part of the company's incentive plans, with specific details on the number of options available and the actual shares exercised during the period [1][2] Summary by Sections Stock Option Exercise Results - For the 2022 first phase stock option incentive plan, 606,712 options were available for exercise, with 207,933 shares exercised, representing 34.27% of the total [1] - For the 2023 first phase stock option incentive plan, 3,932,677 options were available, with 197,594 shares exercised, accounting for 5.02% of the total [1] - The second phase of the 2023 plan had 4,036,498 options available, with 2,096,428 shares exercised, which is 51.94% of the total [2] Stock Listing and Trading - Shares obtained through the stock option exercise will be listed for trading on the second trading day after the exercise date [3] Approval and Implementation of Incentive Plans - The 2022 first phase stock option incentive plan was approved on April 7, 2022, with a total of 3,935,812 options granted to 515 eligible participants [4][6] - The 2023 first phase stock option incentive plan was approved on August 7, 2023, granting 19,606,675 options to 1,143 participants [17][18] Adjustments and Cancellations - The exercise price for the 2022 plan was adjusted multiple times due to profit distributions, with the final price set at 73.63 yuan per share [11][21] - Several stock options have been canceled over time due to various reasons, including non-exercise by participants [7][20] Financial Impact - The total funds raised from the stock option exercises amount to 347,324,192.01 yuan, which will be used to supplement the company's working capital [25][26] - The newly issued shares from the stock option exercises are not expected to have a significant impact on the company's financial status or operational results [26]

Group 1 - The company announced a share repurchase plan with a total amount between RMB 150 million and RMB 300 million, with a repurchase price cap adjusted to RMB 19.77 per share after a dividend distribution [2][3] - As of September 2025, the company has repurchased a total of 1,138,950 shares, accounting for approximately 0.05% of the total share capital, with a total expenditure of RMB 18,338,151 [3][4] Group 2 - The company's consolidated revenue for September 2025 was RMB 5,958,939,681.16, representing a year-on-year increase of 0.10% and a month-on-month increase of 7.23% [8] - For the first nine months of 2025, the consolidated revenue was RMB 43,641,175,541.80, a decrease of 0.83% compared to the same period last year [8] - The consolidated revenue for the third quarter of 2025 was RMB 16,427,474,248.20, a year-on-year decrease of 1.16% but a quarter-on-quarter increase of 21.10% [8] Group 3 - In the third quarter of 2025, the company converted RMB 24,000 of convertible bonds into 1,288 shares, with a total of RMB 3,449,797,000 of convertible bonds remaining unconverted, accounting for 99.9941% of the total issuance [10][15] - The stock option incentive plan saw 4,667,160 shares exercised in the third quarter of 2025, with a total of 14,553,565 shares exercised since the plan's inception [11][36] Group 4 - The company has made adjustments to the stock option incentive plan due to changes in the number of eligible participants and performance evaluations, resulting in a reduction of the total number of options granted [19][25] - The exercise price for the 2023 stock option incentive plan was adjusted to RMB 14.04 per share for the third quarter of 2025 [33][36]

Core Viewpoint - The company has adjusted the exercise price of its 2024 stock option incentive plan from 19.97 yuan to 18.67 yuan per share, following the completion of its profit distribution plans and in accordance with the provisions of the incentive plan [6][7][34]. Group 1: Approval Process - The company held multiple board and supervisory meetings to review and approve the stock option incentive plan, ensuring compliance with relevant regulations [30][31][33]. - The first temporary shareholders' meeting in 2024 authorized the board to handle matters related to the stock option incentive plan [30][34]. - The company publicly solicited voting rights from shareholders regarding the incentive plan, with no objections received during the public notice period [31][32]. Group 2: Adjustment Details - The adjustment of the exercise price was necessitated by the company's profit distribution, which included cash dividends of 3.00 yuan per 10 shares and 10.00 yuan per 10 shares for different periods [6][34]. - The new exercise price was calculated by deducting the total cash dividend from the previous exercise price, resulting in an adjusted price of 18.67 yuan per share [7][34]. Group 3: Impact on the Company - The adjustment of the exercise price is in line with the regulations and will not materially affect the company's financial status or operational results [8]. - The company’s remuneration and assessment committee confirmed that the adjustment process was legal and effective, supporting the new exercise price [9][45]. Group 4: Legal and Financial Opinions - Legal opinions confirm that the adjustment has received necessary approvals and complies with relevant laws and regulations [11][46]. - The independent financial advisor also affirmed that the stock option incentive plan adjustments meet the required conditions and legal standards [47].

Core Viewpoint - The announcement details the completion of the stock option incentive plan for 2025, including the number of options granted and the procedures followed for approval and registration [2][4][19] Group 1: Stock Option Details - Stock option reserve grant registration completion date: September 26, 2025 [2] - Total number of stock options reserved for grant: 1.2 million [2] - Number of individuals receiving stock options: 18 [2] - Source of stock: Company will issue A-share common stock to the incentive recipients [2] Group 2: Decision-Making Process - The decision-making process for the incentive plan included multiple board meetings and approvals, starting from March 31, 2025, with the final approval from the shareholders on April 17, 2025 [3][4][5] - The board authorized the grant of stock options on April 25, 2025, with a total of 4.8 million options granted to 25 recipients [5][6] Group 3: Grant Conditions and Terms - The effective period of the incentive plan is from the first grant date until all options are exercised or canceled, not exceeding 48 months [6] - The waiting period for the options is set at 12 months and 24 months for different grants [7] - The exercise price for the reserved stock options is set at 14.95 yuan per option [9] Group 4: Performance Assessment - The performance assessment for the stock options includes company-level and individual-level evaluations, with specific targets set for the years 2025 and 2026 [12][13] - The company-level performance targets are linked to the net profit as per the audited consolidated financial statements [12] Group 5: Financial Impact - The fair value of the stock options was calculated using the Black-Scholes model, with the underlying stock price at 22.14 yuan per share on the authorization date [14][18] - The estimated incentive costs will be recognized in the company's regular operating results, with a minor expected impact on financial performance [15][18]

Core Points - Shanghai Junshi Biosciences Co., Ltd. announced a stock option incentive plan for 2025, proposing to grant a total of 25.965871 million rights [1] - The initial grant consists of 25.15 million options, accounting for 96.86% of the total, with Chairman Xiong Jun receiving 8 million options, representing 30.81% of the total options granted [1] - A total of 234 other incentive recipients will receive 17.15 million options, which is 66.05% of the total [1] - The reserved portion of the incentive plan is 815,871 options, making up 3.14% of the total [1] - The plan complies with relevant regulations, and the incentive recipients do not include independent directors, supervisors, or senior executives [1] - The reserved incentive recipients will be determined and disclosed within 12 months [1]